Clinical efficacy of Kang'ai injection combined with sorafenib in patients with advanced renal carcinoma
Objective To investigate the clinical efficacy of Kang'ai injection combined with sorafenib in the treat-ment of advanced renal carcinoma.Method A total of 50 patients with advanced renal carcinoma were divided into sorafenib group(n=24)and Kang'ai group(n=26)according to different treatment methods.Sorafenib group was treated with sorafenib,and Kang'ai group was treated with Kang'ai injection on the basis of sorafenib group.The efficacy,im-mune function indexes(CD3+,CD4+,CD8+,CD4+/CD8+),adverse reactions and quality of life were compared between the two groups.Result The total effective rate of Kang'ai group was higher than that of sorafenib group,the difference was statistically significant(P<0.05).After treatment,the levels of CD3+,CD4+ and CD4+/CD8+ in both groups were higher than those before treatment,while the levels of CD8+ were lower than those before treatment,and the levels of CD3+,CD4+ and CD4+/CD8+ in Kang'ai group were higher than those in sorafenib group,while the level of CD8+ was lower than that in sorafenib group,the differences were statistically significant(P<0.05).After treatment,the scores of physical function,cognitive function,social function,emotional function and role function in the two groups were higher than those before treatment,and the scores of physical function,cognitive function,social function,emotional function and role function in Kang'ai group were higher than those in sorafenib group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Kang'ai injection combined with sorafenib can improve the clinical efficacy,immune function and quality of life of patients with advanced renal carcinoma without increasing adverse reactions.
advanced renal carcinomaKang'ai injectionsorafenibclinical efficacyquality of life
万方数据
维普
